Cargando…

Ultra-high-throughput Ca(2+) assay in platelets to distinguish ITAM-linked and G-protein-coupled receptor activation

Antiplatelet drugs targeting G-protein-coupled receptors (GPCRs), used for the secondary prevention of arterial thrombosis, coincide with an increased bleeding risk. Targeting ITAM-linked receptors, such as the collagen receptor glycoprotein VI (GPVI), is expected to provide a better antithrombotic-...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Delia I., Provenzale, Isabella, Cheung, Hilaire Y.F., van Groningen, Jan, Tullemans, Bibian M.E., Veninga, Alicia, Dunster, Joanne L., Honarnejad, Saman, van den Hurk, Helma, Kuijpers, Marijke J.E., Heemskerk, Johan W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762394/
https://www.ncbi.nlm.nih.gov/pubmed/35072010
http://dx.doi.org/10.1016/j.isci.2021.103718
Descripción
Sumario:Antiplatelet drugs targeting G-protein-coupled receptors (GPCRs), used for the secondary prevention of arterial thrombosis, coincide with an increased bleeding risk. Targeting ITAM-linked receptors, such as the collagen receptor glycoprotein VI (GPVI), is expected to provide a better antithrombotic-hemostatic profile. Here, we developed and characterized an ultra-high-throughput (UHT) method based on intracellular [Ca(2+)](i) increases to differentiate GPVI and GPCR effects on platelets. In 96-, 384-, or 1,536-well formats, Calcium-6-loaded human platelets displayed a slow-prolonged or fast-transient [Ca(2+)](i) increase when stimulated with the GPVI agonist collagen-related peptide or with thrombin and other GPCR agonists, respectively. Semi-automated curve fitting revealed five parameters describing the Ca(2+) responses. Verification of the UHT assay was done with a robustness compound library and clinically relevant platelet inhibitors. Taken together, these results present proof of principle of distinct receptor-type-dependent Ca(2+) signaling curves in platelets, which allow identification of new inhibitors in a UHT way.